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Ovarian cancer remains one of the most lethal malignan-
cies in developed countries and recently no improvement
in disease free survival (DFS) and overall survival (OS)
has been numbered for conventional therapies. Immu-
notherapy could be employed as consolidation treatment
after standard therapies in patients in which disease and
immune suppression is minimal. Furthermore, epitope
spread and new adjutants have been found to signifi-
cantly increase the efficacy of novel immunotherapic
strategies.This Phase I/II study aimed to improve vaccine
potency and enhance immune response of two mucins
(MUC-1 and CEA) and Erb-B2 tumour associated anti-
gens (TAAs), with the co-administration of a new adju-
vant combination: Montanide ISA51 plus GM-CSF.
Keyhole Limpet Hemocyanin (KLH) was adopted as
immunological tracker.Ten disease-free HLA-A2 aplo-
type high-risk serous advanced stage ovarian cancer
patients underwent a two-groups safety clinical trial
vaccination protocol at “Sapienza” University of Rome
from 2007 to 2010. CEA, Erb-B2 and MUC1 expression
rates on primary tumours were 40%, 30% and 100%,
respectively. Group A (8 patients) received 100μg of each
peptide per dose accordingly to the immunohistochemi-
cally antigen expression, whereas GroupB (2 patients)
was vaccinated with all the peptide regardless TAAs
expression at the dose of 500μg each. Vaccination sche-
dule included 6 consecutive peptide vaccine administra-
tions and a recall dose at 3 months from the sixth dose.
Results revealed the vaccine to be safe and feasible in
ovarian cancer patients. Side effects accounts for ECOG
scale 1-2 levels signs (itch, erythema and tumescence at
injection site) and symptoms (fever, fatigue and malaise),
for both the dose-administered. Good compliance was
found to vaccine schedule in all patients enrolled.
Secondary endpoints results revealed a 5 years 50%
(3/6 patients) DFS and a 83% (5/6 patients) OS in FIGO
stages IIIc-IV ovarian cancer patients (60%; 6/10 patients).
Moreover, immunological and clinical correlation analysis
revealed a significant increased IFNg CD8+ specific T-cells
production along with vaccination steps (c2=6.67;
p<0.009) in the subgroup of patients who did not recur vs.
controls (mean follow up: 845.1 days; range 55-1523). The
highest number of vaccine induced specific CD8+ cells
were found at the end of the 6 doses although high levels
of T-cells could be also re-induced by the recall boost.
A significantly higher specific immune response was
observed in the group B.
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